Fempro 2.5 mg Tablet is an oral medication containing FDA-approved Letrozole (2.5 mg) as its active ingredient. It is prescribed primarily for the treatment of hormone receptor-positive Breast Cancer in postmenopausal women and for ovulation induction in women with infertility related to conditions such as Polycystic Ovary Syndrome (PCOS) and Anovulation (absence of ovulation). Cipla Ltd manufactures Fempro 2.5 mg Tablet in GMP-compliant facilities.
Letrozole belongs to the class of medications known as aromatase inhibitors. It works by blocking the aromatase enzyme, which converts androgens into estrogen in peripheral tissues such as fat and muscle, as well as the adrenal glands. In postmenopausal women, in whom the ovaries are no longer the primary source of estrogen, peripheral conversion is responsible for most circulating estrogen.
By inhibiting aromatase, Letrozole significantly reduces estrogen levels throughout the body, depriving hormone receptor-positive cancer cells of the hormonal stimulus they depend on for growth and proliferation. In the case of infertility treatment, the temporary reduction in estrogen caused by Letrozole increases the secretion of Follicle-stimulating Hormone (FSH), which stimulates follicular development and ovulation.
This mechanism makes Letrozole an effective and increasingly preferred alternative to Clomiphene Citrate for ovulation induction, particularly in women with PCOS. It is typically taken for 5 consecutive days early in the menstrual cycle as directed by a doctor.
The most common side effects include hot flashes, joint pain, fatigue, nausea, and headache. Prolonged use can reduce bone mineral density due to sustained estrogen suppression, and bone health monitoring is recommended for patients on long-term therapy. Inform a doctor of any history of Osteoporosis, liver disease, or cardiovascular conditions before starting treatment.
Store Fempro 2.5 mg Tablet in a dry, cool place below 30°C, away from sunlight and moisture. Keep out of reach of children and do not use after the expiry date printed on the pack.
Fempro 2.5 mg Tablet offers targeted clinical benefits for women managing hormone-sensitive Breast Cancer or fertility-related challenges. Some of the benefits include:
Fempro 2.5 mg is a prescription medication that must be used strictly as directed by a healthcare professional. Here are the general guidelines:
Currently, Fempro tablets are available in a single strength option at Cheap Medicine Shop. However, you can consider the following effective substitutes available:
| Femara 2.5 mg Tablet | $29.40/10 tablets |
| Mamazol 2.5 mg Tablet | $7.30/10 tablets |
Like any medication, Fempro 2.5 mg can cause some side effects that are generally mild and subside as the body adjusts to treatment. However, consult a healthcare professional if they persist or worsen:
Liver Disease
Fempro 2.5 mg Tablet should be used with caution in patients with liver disease. Letrozole is metabolized in the liver, and severe impairment may significantly reduce its clearance, leading to increased medicine exposure and a higher risk of adverse effects. Inform a doctor of any liver conditions before initiating treatment, as dose adjustment or additional monitoring may be required.
Kidney Impairment
The Letrozole tablet should be used with caution in patients with kidney disease. Dose adjustment may be needed in some cases. Always inform a doctor of any existing kidney conditions before starting treatment.
Pregnant and Breastfeeding women
Fempro 2.5 mg Tablet must not be used during pregnancy as it can harm the baby. Letrozole should not be used while breastfeeding as the medicine can pass through breastmilk. Effective contraception is recommended for premenopausal women using this medication.
Avoid
Do not use Fempro 2.5 mg in patients with known hypersensitivity to Letrozole or any inactive ingredient. It is not indicated for use in premenopausal women for Breast Cancer treatment. Inform a doctor of all current medications before starting Fempro, particularly other hormonal therapies, as interactions may affect treatment outcomes.
Yes, prolonged use of Letrozole reduces circulating estrogen levels, which play an important role in maintaining bone density. Long-term therapy may increase the risk of Osteoporosis and fractures. Regular bone density monitoring and supplementation with calcium and vitamin D are typically recommended for patients on extended Letrozole treatment.
Yes, Fempro 2.5 m is prescribed for ovulation induction in women with infertility related to PCOS or Anovulation. It temporarily lowers estrogen levels, stimulating FSH release and promoting follicular development. It is now widely considered a first-line option for ovulation induction in women with PCOS.
Inform a doctor of any history of Osteoporosis, liver disease, cardiovascular conditions, or hypersensitivity to Letrozole before starting treatment. Bone density should be monitored during long-term use. Effective contraception is essential for premenopausal women. Do not self-adjust the dose or stop therapy abruptly without medical guidance.
Yes, hot flashes are a commonly reported side effect of Letrozole. They occur because estrogen suppression disrupts the body's temperature-regulation mechanisms. Hot flashes are generally mild to moderate and tend to become less frequent with continued use. Inform a doctor if they are severe or persistent.
For ovulation induction, ovulation typically occurs within 5 to 10 days of completing the five-day course. For Breast Cancer treatment, Letrozole works continuously to suppress estrogen over the course of therapy, and its clinical benefits are assessed over months and years through oncological monitoring and follow-up.
Yes, joint and muscle pain are commonly reported with Letrozole therapy, particularly in women using it for Breast Cancer treatment over an extended period. This is related to reduced estrogen levels, which affect joint lubrication and inflammation. Inform a doctor if joint pain is severe or affects daily functioning.
Yes, Fempro 2.5 mg is prescribed for long-term use in the treatment of Breast Cancer and is considered safe when monitored appropriately. Regular assessment of bone density, cholesterol levels, and cardiovascular health is recommended during extended therapy to promptly identify and manage emerging concerns.